Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 8
2004 10
2005 5
2006 8
2007 4
2008 8
2009 8
2010 11
2011 14
2012 15
2013 9
2014 8
2015 9
2016 11
2017 13
2018 9
2019 14
2020 11
2021 5
2022 9
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

168 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
O'Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, Esteban E, Isla D, Martinez-Marti A, Faehling M, Tsuboi M, Lee JS, Nakagawa K, Yang J, Samkari A, Keller SM, Mauer M, Jha N, Stahel R, Besse B, Peters S; EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 Investigators. O'Brien M, et al. Among authors: stahel r. Lancet Oncol. 2022 Oct;23(10):1274-1286. doi: 10.1016/S1470-2045(22)00518-6. Epub 2022 Sep 12. Lancet Oncol. 2022. PMID: 36108662 Clinical Trial.
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N; MabThera International Trial (MInT) Group. Pfreundschuh M, et al. Among authors: stahel r. Lancet Oncol. 2011 Oct;12(11):1013-22. doi: 10.1016/S1470-2045(11)70235-2. Epub 2011 Sep 21. Lancet Oncol. 2011. PMID: 21940214 Clinical Trial.
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M; MabThera International Trial Group. Pfreundschuh M, et al. Among authors: stahel r. Lancet Oncol. 2006 May;7(5):379-91. doi: 10.1016/S1470-2045(06)70664-7. Lancet Oncol. 2006. PMID: 16648042 Clinical Trial.
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
Homicsko K, Zygoura P, Norkin M, Tissot S, Shakarishvili N, Popat S, Curioni-Fontecedro A, O'Brien M, Pope A, Shah R, Fisher P, Spicer J, Roy A, Gilligan D, Rusakiewicz S, Fortis E, Marti N, Kammler R, Finn SP, Coukos G, Dafni U, Peters S, Stahel RA. Homicsko K, et al. Among authors: stahel ra. J Immunother Cancer. 2023 Oct;11(10):e007585. doi: 10.1136/jitc-2023-007585. J Immunother Cancer. 2023. PMID: 37880184 Free PMC article.
Hippo/YAP pathway for targeted therapy.
Felley-Bosco E, Stahel R. Felley-Bosco E, et al. Among authors: stahel r. Transl Lung Cancer Res. 2014 Apr;3(2):75-83. doi: 10.3978/j.issn.2218-6751.2014.02.03. Transl Lung Cancer Res. 2014. PMID: 25806284 Free PMC article. Review.
Treatment and detection of ALK-rearranged NSCLC.
Peters S, Taron M, Bubendorf L, Blackhall F, Stahel R. Peters S, et al. Among authors: stahel r. Lung Cancer. 2013 Aug;81(2):145-54. doi: 10.1016/j.lungcan.2013.03.017. Epub 2013 Jun 12. Lung Cancer. 2013. PMID: 23769207 Review.
Malignant pleural mesothelioma.
Stahel RA, Felley-Bosco E, Opitz I, Weder W. Stahel RA, et al. Future Oncol. 2009 Apr;5(3):391-402. doi: 10.2217/fon.09.7. Future Oncol. 2009. PMID: 19374545 Review.
PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.
Peters S, Kerr KM, Stahel R. Peters S, et al. Among authors: stahel r. Cancer Treat Rev. 2018 Jan;62:39-49. doi: 10.1016/j.ctrv.2017.10.002. Epub 2017 Oct 23. Cancer Treat Rev. 2018. PMID: 29156447 Free article. Review.
Successful publishing: how to get your paper accepted.
Audisio RA, Stahel RA, Aapro MS, Costa A, Pandey M, Pavlidis N. Audisio RA, et al. Among authors: stahel ra. Surg Oncol. 2009 Dec;18(4):350-6. doi: 10.1016/j.suronc.2008.09.001. Epub 2008 Oct 11. Surg Oncol. 2009. PMID: 18849161 Review.
Obere Einflussstauung - Vena-cava-superior-Syndrom.
Nater H, Niggemeier V, Stahel RA, Franzen D. Nater H, et al. Among authors: stahel ra. Praxis (Bern 1994). 2013 Apr 15;102(9):503-12. doi: 10.1024/1661-8157/a001306. Praxis (Bern 1994). 2013. PMID: 23608409 Free article. German. No abstract available.
168 results